3billion Launches Genomic Newborn Screening Service 3B-NEO

3billion announced in a press release the launch of 3B-NEO, a genomic newborn screening service designed to identify genetic risks before symptoms appear. The service analyzes 595 genes associated with serious childhood-onset disorders where early intervention may improve outcomes.

3B-NEO focuses on clinically actionable conditions including inherited metabolic, immunologic, neuromuscular, and cardiovascular disorders. Rather than expanding the number of genes tested, it prioritizes findings that can guide medical decisions for physicians and families.

The screening is available in two formats: a Whole Exome Sequencing standard test and a Whole Genome Sequencing premium test. Results are typically provided within two weeks after the sample is received. Hospitals, pediatric clinics, and obstetrics practices can offer the service without building their own genomic testing infrastructure, while parents may request testing through participating providers.

3billion plans to expand collaborations with healthcare providers globally, including regions with limited access to advanced genetic testing. The company, founded in 2016, currently provides genomic diagnostics and interpretation services in more than 75 countries.